CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
CG Oncology will present the final results from its Phase 2 CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab for BCG-unresponsive high-risk NMIBC at the ASCO 2024 Annual Meeting.
May 24, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CG Oncology will present final Phase 2 results of its CORE-001 study at the ASCO 2024 Annual Meeting, which could significantly impact the company's stock price.
The presentation of final Phase 2 results at a major conference like ASCO could lead to increased investor interest and potential stock price appreciation, especially if the results are positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100